What empiric antibiotic therapy is recommended for community‑acquired pneumonia in otherwise healthy adults, adults with comorbidities, and hospitalized patients?

Empiric Antibiotic Therapy for Community-Acquired Pneumonia

For healthy outpatient adults without comorbidities, use amoxicillin 1g three times daily as first-line therapy; for outpatients with comorbidities, use either combination therapy with amoxicillin/clavulanate plus a macrolide OR monotherapy with a respiratory fluoroquinolone; for hospitalized non-ICU patients, use a respiratory fluoroquinolone or beta-lactam plus macrolide; and for ICU patients, use a beta-lactam plus either azithromycin or a respiratory fluoroquinolone 1.

Healthy Outpatients (No Comorbidities)

The 2019 ATS/IDSA guidelines provide clear stratification based on patient characteristics 1:

• First choice: Amoxicillin 1g three times daily (strong recommendation, moderate quality evidence)
• Alternative: Doxycycline 100mg twice daily (conditional recommendation, low quality evidence)
• Macrolides ONLY if local pneumococcal resistance <25%: Azithromycin 500mg day 1, then 250mg daily; OR clarithromycin 500mg twice daily; OR clarithromycin ER 1000mg daily (conditional recommendation, moderate quality evidence)

Critical caveat: Macrolide monotherapy should be avoided in most U.S. regions due to widespread pneumococcal resistance exceeding 25% 1.

Outpatients with Comorbidities

For patients with chronic heart, lung, liver, or renal disease; diabetes mellitus; alcoholism; malignancy; or asplenia, you have two equally acceptable approaches 1:

Option 1: Combination Therapy (Strong Recommendation)

• Beta-lactam component:
  • Amoxicillin/clavulanate 500mg/125mg three times daily, OR
  • Amoxicillin/clavulanate 875mg/125mg twice daily, OR
  • Amoxicillin/clavulanate 2000mg/125mg twice daily, OR
  • Cefpodoxime 200mg twice daily, OR
  • Cefuroxime 500mg twice daily
• PLUS macrolide (azithromycin or clarithromycin as above) OR doxycycline 100mg twice daily

Option 2: Monotherapy (Strong Recommendation)

• Respiratory fluoroquinolone:
  • Levofloxacin 750mg daily, OR
  • Moxifloxacin 400mg daily, OR
  • Gemifloxacin 320mg daily

Hospitalized Non-ICU Patients

For patients requiring hospitalization but not ICU-level care 1, 2:

• Respiratory fluoroquinolone (levofloxacin, moxifloxacin, or gemifloxacin), OR
• Beta-lactam PLUS macrolide combination

Practical consideration: Patients can typically be switched from IV to oral antibiotics within the first 3 days once they show clinical improvement and can tolerate oral medications 3.

Severe CAP (ICU Admission)

For patients meeting 2007 IDSA/ATS severe CAP criteria requiring ICU admission 1, 2:

Standard Severe CAP

• Beta-lactam (third-generation cephalosporin, piperacillin/tazobactam) PLUS
• Azithromycin OR respiratory fluoroquinolone

Pseudomonas Risk Factors Present

Use antipseudomonal coverage 2, 3:

• Antipseudomonal beta-lactam (piperacillin/tazobactam, imipenem/cilastatin, meropenem, doripenem, or cefepime) PLUS
• Aminoglycoside PLUS
• Azithromycin OR antipseudomonal fluoroquinolone (levofloxacin or ciprofloxacin)

MRSA Risk Factors Present

Add 2, 3:

• Vancomycin OR linezolid, OR
• Ceftaroline for resistant cases

Duration of Therapy: Updated 2025 Recommendations

The 2025 ATS guidelines introduce a personalized, stability-based approach 4, 5, 6:

• Non-severe/moderate CAP with clinical stability at day 3: Minimum 3 days of antibiotics (rather than ≥5 days)
• Clinical stability achieved by day 5: 5 days total duration
• Severe CAP requiring ICU: 5 or more days of antibiotics
• Uncomplicated CAP without early stability: 7 days maximum

Clinical stability criteria typically include: temperature normalization, heart rate <100 bpm, respiratory rate <24/min, systolic BP ≥90 mmHg, oxygen saturation ≥90%, and ability to take oral medications 5.

Special Consideration: Positive Viral Testing

The 2025 guidelines suggest NOT prescribing antibiotics for otherwise healthy outpatients with positive viral testing alone, though this is based on very low-quality evidence 4, 6. However, antibiotics should still be administered if:

• Imaging findings consistent with bacterial pneumonia are present
• Patient has comorbidities
• Patient requires hospitalization

Corticosteroids

Use corticosteroids in severe CAP (decreases risk of ARDS and shortens treatment length when given within 36 hours of admission), but recommend against their use in non-severe pneumonia 4, 2, 6.

Evidence Quality Note

The guideline panel acknowledges that RCTs provide limited evidence of superiority of one regimen over another due to small sample sizes and rare occurrence of hard outcomes like mortality 1. The recommendations therefore balance microbiological coverage of likely pathogens (particularly Streptococcus pneumoniae), local resistance patterns, and practical clinical considerations.